Current status of pharmacogenomics testing for anti-tumor drug therapies: Approaches to non-melanoma skin cancer

Rebecca Grealy, Lyn R. Griffiths

Research output: Contribution to journalReview articleResearchpeer-review

1 Citation (Scopus)

Abstract

Skin cancer is one of the most commonly occurring cancer types, with substantial social, physical, and financial burdens on both individuals and societies. Although the role of UV light in initiating skin cancer development has been well characterized, genetic studies continue to show that predisposing factors can influence an individuals susceptibility to skin cancer and response to treatment. In the future, it is hoped that genetic profiles, comprising a number of genetic markers collectively involved in skin cancer susceptibility and response to treatment or prognosis, will aid in more accurately informing practitioners choices of treatment. Individualized treatment based on these profiles has the potential to increase the efficacy of treatments, saving both time and money for the patient by avoiding the need for extensive or repeated treatment. Increased treatment responses may in turn prevent recurrence of skin cancers, reducing the burden of this disease on society. Currently existing pharmacogenomic tests, such as those that assess variation in the metabolism of the anticancer drug fluorouracil, have the potential to reduce the toxic effects of anti-tumor drugs used in the treatment of non-melanoma skin cancer (NMSC) by determining individualized appropriate dosage. If the savings generated by reducing adverse events negate the costs of developing these tests, pharmacogenomic testing may increasingly inform personalized NMSC treatment.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
JournalMolecular Diagnosis and Therapy
Volume13
Issue number2
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Skin Neoplasms
Drug Therapy
Neoplasms
Therapeutics
Pharmacogenomic Testing
Poisons
Pharmacogenetics
Ultraviolet Rays
Genetic Markers
Fluorouracil
Causality
Pharmaceutical Preparations
Costs and Cost Analysis
Recurrence

Cite this

@article{56a750407c054e5692cc9b025ac58bea,
title = "Current status of pharmacogenomics testing for anti-tumor drug therapies: Approaches to non-melanoma skin cancer",
abstract = "Skin cancer is one of the most commonly occurring cancer types, with substantial social, physical, and financial burdens on both individuals and societies. Although the role of UV light in initiating skin cancer development has been well characterized, genetic studies continue to show that predisposing factors can influence an individuals susceptibility to skin cancer and response to treatment. In the future, it is hoped that genetic profiles, comprising a number of genetic markers collectively involved in skin cancer susceptibility and response to treatment or prognosis, will aid in more accurately informing practitioners choices of treatment. Individualized treatment based on these profiles has the potential to increase the efficacy of treatments, saving both time and money for the patient by avoiding the need for extensive or repeated treatment. Increased treatment responses may in turn prevent recurrence of skin cancers, reducing the burden of this disease on society. Currently existing pharmacogenomic tests, such as those that assess variation in the metabolism of the anticancer drug fluorouracil, have the potential to reduce the toxic effects of anti-tumor drugs used in the treatment of non-melanoma skin cancer (NMSC) by determining individualized appropriate dosage. If the savings generated by reducing adverse events negate the costs of developing these tests, pharmacogenomic testing may increasingly inform personalized NMSC treatment.",
author = "Rebecca Grealy and Griffiths, {Lyn R.}",
year = "2009",
doi = "10.2165/01250444-200913020-00001",
language = "English",
volume = "13",
pages = "65--72",
journal = "Molecular Diagnosis",
issn = "1084-8592",
publisher = "Adis International Ltd",
number = "2",

}

Current status of pharmacogenomics testing for anti-tumor drug therapies : Approaches to non-melanoma skin cancer. / Grealy, Rebecca; Griffiths, Lyn R.

In: Molecular Diagnosis and Therapy, Vol. 13, No. 2, 2009, p. 65-72.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Current status of pharmacogenomics testing for anti-tumor drug therapies

T2 - Approaches to non-melanoma skin cancer

AU - Grealy, Rebecca

AU - Griffiths, Lyn R.

PY - 2009

Y1 - 2009

N2 - Skin cancer is one of the most commonly occurring cancer types, with substantial social, physical, and financial burdens on both individuals and societies. Although the role of UV light in initiating skin cancer development has been well characterized, genetic studies continue to show that predisposing factors can influence an individuals susceptibility to skin cancer and response to treatment. In the future, it is hoped that genetic profiles, comprising a number of genetic markers collectively involved in skin cancer susceptibility and response to treatment or prognosis, will aid in more accurately informing practitioners choices of treatment. Individualized treatment based on these profiles has the potential to increase the efficacy of treatments, saving both time and money for the patient by avoiding the need for extensive or repeated treatment. Increased treatment responses may in turn prevent recurrence of skin cancers, reducing the burden of this disease on society. Currently existing pharmacogenomic tests, such as those that assess variation in the metabolism of the anticancer drug fluorouracil, have the potential to reduce the toxic effects of anti-tumor drugs used in the treatment of non-melanoma skin cancer (NMSC) by determining individualized appropriate dosage. If the savings generated by reducing adverse events negate the costs of developing these tests, pharmacogenomic testing may increasingly inform personalized NMSC treatment.

AB - Skin cancer is one of the most commonly occurring cancer types, with substantial social, physical, and financial burdens on both individuals and societies. Although the role of UV light in initiating skin cancer development has been well characterized, genetic studies continue to show that predisposing factors can influence an individuals susceptibility to skin cancer and response to treatment. In the future, it is hoped that genetic profiles, comprising a number of genetic markers collectively involved in skin cancer susceptibility and response to treatment or prognosis, will aid in more accurately informing practitioners choices of treatment. Individualized treatment based on these profiles has the potential to increase the efficacy of treatments, saving both time and money for the patient by avoiding the need for extensive or repeated treatment. Increased treatment responses may in turn prevent recurrence of skin cancers, reducing the burden of this disease on society. Currently existing pharmacogenomic tests, such as those that assess variation in the metabolism of the anticancer drug fluorouracil, have the potential to reduce the toxic effects of anti-tumor drugs used in the treatment of non-melanoma skin cancer (NMSC) by determining individualized appropriate dosage. If the savings generated by reducing adverse events negate the costs of developing these tests, pharmacogenomic testing may increasingly inform personalized NMSC treatment.

UR - http://www.scopus.com/inward/record.url?scp=67650281041&partnerID=8YFLogxK

U2 - 10.2165/01250444-200913020-00001

DO - 10.2165/01250444-200913020-00001

M3 - Review article

VL - 13

SP - 65

EP - 72

JO - Molecular Diagnosis

JF - Molecular Diagnosis

SN - 1084-8592

IS - 2

ER -